METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes.

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• METTL3 is the primary enzyme responsible for RNA N⁶ -methyladenosine (m⁶ A) methylation.
• m⁶ A modification plays crucial roles in various cellular processes.
• Targeting METTL3 offers a potential therapeutic strategy.

Purpose of the Study:

• To identify and characterize a selective inhibitor of the METTL3 methyltransferase.
• To evaluate the compound's efficacy in reducing cellular m⁶ A levels.
• To assess the selectivity of the inhibitor against other RNA modifications.

Main Methods:

• Structure-based drug discovery approach.
• Biochemical assays to determine inhibitor potency (IC50).
• Cell-based assays to measure mRNA m⁶ A levels after treatment.
• Analysis of other RNA modifications (m¹ A, m⁶ A_m , m⁷ G) to assess selectivity.

Main Results:

• Identification of a potent METTL3 inhibitor with 280 nM potency.
• Enantiomer of the inhibitor showed significantly lower activity (100-fold less).
• Dose-dependent reduction in mRNA m⁶ A levels observed in cell lines within 16 hours, sustained for at least 6 days.
• No alteration in levels of other RNA modifications (m¹ A, m⁶ A_m , m⁷ G) upon prolonged treatment.

Conclusions:

• A selective and potent METTL3 inhibitor was successfully developed.
• The inhibitor effectively reduces cellular m⁶ A levels in a sustained manner.
• The compound demonstrates selectivity, not affecting other tested RNA modifications, highlighting its potential as a research tool and therapeutic lead.